Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A single-institute study of 43 cases

被引:8
作者
Chen, Irene [1 ]
Zhang, Dongwei [1 ]
Velez, Moises [1 ]
Kovar, Sierra [1 ]
Liao, Xiaoyan [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA
关键词
Neuroendocrine carcinoma; INSM1; SATB2; PD-L1; Prognosis; PD-L1; EXPRESSION; CANCER; COLON;
D O I
10.1016/j.prp.2021.153614
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: To characterize the clinicopathologic and immunohistochemical features of poorly differentiated neuroendocrine carcinomas (NEC) in the gastrointestinal tract. Design: A total of 43 cases were identified and reassessed based on modern classification. Results: The cohort (27M, 16F; median age: 66 years) included 16 (37%) large cell NEC, 12 (28%) small cell NEC, 5 (12%) NEC not otherwise specified, and 10 (23%) mixed adenoneuroendocrine carcinomas. Tumor predominantly involved the colon (n = 14, 33%), rectum (n = 13, 30%), and esophagus (n = 9, 21%). Immunohistochemically, INSM1 was the most sensitive marker for neuroendocrine differentiation (28/28, 100%), followed by synaptophysin (40/43, 93%), CD56 (22/35, 63%), and chromogranin (18/40, 45%). SATB2, CDX2, CK20, CK7, abnormal p53, and PD-L1 was positive in 21/26 (81%), 26/37 (70%), 11/35 (31%), 10/35 (29%), 19/24 (79%), and 12/23 (52%) cases, respectively. Three of 25 (11%) were mismatch repair protein deficient. Of 21 resected tumors, 19 (90%) were >= pT3 and 13 (62%) had nodal metastasis. Twenty-eight (65%) had distant metastasis. The 5-year survival rate was 21%. The prognosis was stage dependent (p < 0.05), but not associated with tumor type, location, or specific immunomarkers. Conclusion: Gastrointestinal NECs are aggressive neoplasms. INSM1, synaptophysin, and SATB2 are sensitive markers, although not site or tumor type specific.
引用
收藏
页数:7
相关论文
共 50 条
[31]   Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas [J].
De-Jun Liu ;
Xue-Liang Fu ;
Wei Liu ;
Lu-Ying Zheng ;
Jun-Feng Zhang ;
Yan-Miao Huo ;
Jiao Li ;
Rong Hua ;
Qiang Liu ;
Yong-Wei Sun .
World Journal of Gastroenterology, 2017, 23 (03) :516-524
[32]   Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas [J].
Liu, De-Jun ;
Fu, Xue-Liang ;
Liu, Wei ;
Zheng, Lu-Ying ;
Zhang, Jun-Feng ;
Huo, Yan-Miao ;
Li, Jiao ;
Hua, Rong ;
Liu, Qiang ;
Sun, Yong-Wei .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (03) :516-524
[33]   A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors [J].
Pelosi, Giuseppe ;
Bianchi, Fabrizio ;
Dama, Elisa ;
Metovic, Jasna ;
Barella, Marco ;
Sonzogni, Angelica ;
Albini, Adriana ;
Papotti, Mauro ;
Gong, Yulan ;
Vijayvergia, Namrata .
ENDOCRINE PATHOLOGY, 2021, 32 (03) :396-407
[34]   Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort [J].
Walter, T. ;
Tougeron, D. ;
Baudin, E. ;
Le Malicot, K. ;
Lecomte, T. ;
Malka, D. ;
Hentic, O. ;
Manfredi, S. ;
Bonnet, I. ;
Guimbaud, R. ;
Coriat, R. ;
Lepere, C. ;
Desauw, C. ;
Thirot-Bidault, A. ;
Dahan, L. ;
Roquin, G. ;
Aparicio, T. ;
Legoux, J-L. ;
Lombard-Bohas, C. ;
Scoazec, J-Y. ;
Lepage, C. ;
Cadiot, G. .
EUROPEAN JOURNAL OF CANCER, 2017, 79 :158-165
[35]   Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis [J].
Puliafito, Ivana ;
Chillari, Federico ;
Russo, Alessandro ;
Cantale, Ornella ;
Sciacca, Dorotea ;
Castorina, Luigi ;
Colarossi, Cristina ;
Franchina, Tindara ;
Vitale, Maria Paola ;
Ricciardi, Giuseppina Rosaria Rita ;
Adamo, Vincenzo ;
Esposito, Francesca ;
Giuffrida, Dario .
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[36]   Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases [J].
Asayama, Masako ;
Fuse, Nozomu ;
Yoshino, Takayuki ;
Yano, Tomonori ;
Tahara, Makoto ;
Doi, Toshihiko ;
Fujii, Satoshi ;
Ohtsu, Atsushi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) :1325-1330
[37]   Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases [J].
Masako Asayama ;
Nozomu Fuse ;
Takayuki Yoshino ;
Tomonori Yano ;
Makoto Tahara ;
Toshihiko Doi ;
Satoshi Fujii ;
Atsushi Ohtsu .
Cancer Chemotherapy and Pharmacology, 2011, 68 :1325-1330
[38]   Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs) [J].
Bardasi, C. ;
Spallanzani, A. ;
Luppi, G. ;
Bertolini, F. ;
Fontana, A. ;
Salati, M. ;
Caputo, F. ;
Santini, C. ;
Cerma, K. ;
Dominici, M. ;
Gelsomino, C. .
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :156-156
[39]   Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience [J].
Bardasi, C. ;
Caputo, F. ;
Santini, C. ;
Cerma, K. ;
Gardini, Casadei A. ;
Andrikou, K. ;
Salati, M. ;
Fontana, A. ;
Spallanzani, A. ;
Bertolini, F. ;
Luppi, G. ;
Gelsomino, F. .
NEUROENDOCRINOLOGY, 2020, 110 :180-180
[40]   The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas [J].
Lee, Hwajeong ;
Fu, Zhiyan ;
Koo, Brandon H. ;
Sheehan, Christine E. ;
Young, Gloria Q. ;
Lin, Jingmei ;
Patil, Deepa T. ;
Yang, Zhaohai .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 37 :30-34